Zacks Research Has Positive Forecast for Humana Q2 Earnings

Humana Inc. (NYSE:HUM - Free Report) - Equities research analysts at Zacks Research lifted their Q2 2025 EPS estimates for shares of Humana in a report issued on Wednesday, May 14th. Zacks Research analyst D. Chatterjee now forecasts that the insurance provider will post earnings per share of $9.71 for the quarter, up from their prior forecast of $5.31. The consensus estimate for Humana's current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana's Q3 2025 earnings at $1.68 EPS, Q4 2025 earnings at ($6.71) EPS, Q1 2026 earnings at $6.70 EPS, Q2 2026 earnings at $5.05 EPS, Q3 2026 earnings at $2.20 EPS, Q4 2026 earnings at ($2.92) EPS, FY2026 earnings at $11.02 EPS, Q1 2027 earnings at $7.48 EPS and FY2027 earnings at $18.80 EPS.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. During the same quarter last year, the firm posted $7.23 EPS. The company's quarterly revenue was up 8.4% on a year-over-year basis.

HUM has been the subject of several other research reports. Guggenheim assumed coverage on shares of Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price for the company. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 target price on shares of Humana in a report on Thursday, May 1st. JPMorgan Chase & Co. reduced their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Finally, Robert W. Baird lifted their target price on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Seventeen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Humana currently has a consensus rating of "Hold" and a consensus price target of $286.81.

Humana Stock Performance

Shares of HUM stock opened at $237.42 on Monday. The company has a market capitalization of $28.65 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.05 and a beta of 0.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company has a 50-day simple moving average of $262.94 and a 200 day simple moving average of $269.57. Humana has a 52 week low of $212.45 and a 52 week high of $406.46.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.49%. The ex-dividend date of this dividend is Friday, June 27th. Humana's payout ratio is presently 25.04%.

Hedge Funds Weigh In On Humana

Hedge funds and other institutional investors have recently made changes to their positions in the company. FPC Investment Advisory Inc. acquired a new position in shares of Humana in the 4th quarter valued at approximately $27,000. Centricity Wealth Management LLC acquired a new position in Humana during the 4th quarter worth approximately $30,000. Cary Street Partners Investment Advisory LLC increased its position in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after purchasing an additional 46 shares in the last quarter. LFA Lugano Financial Advisors SA increased its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Finally, Riverview Trust Co acquired a new position in Humana during the 1st quarter worth approximately $34,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.